Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - lamivudine, quantity: 10 mg/ml - oral liquid, solution - excipient ingredients: citric acid; sodium hydroxide; propyl hydroxybenzoate; purified water; hydrochloric acid; sodium citrate dihydrate; methyl hydroxybenzoate; propylene glycol; sucrose; flavour - 3tc (lamivudine) in combination with other antiretroviral agents is indicated for the treatment of hiv infected adults and children.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - lamivudine 10 mg/ml;   - oral solution - 10 mg/ml - active: lamivudine 10 mg/ml   excipient: banana flavour 59.256 ap0551 citric acid methyl hydroxybenzoate propyl hydroxybenzoate propylene glycol purified water sodium citrate dihydrate strawberry flavour 057883 ap0551 sucrose - 3tc in combination with other anti-retroviral agents is indicated for the treatment of hiv infected adults and children.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

rex medical ltd - lamivudine 10 mg/ml - oral solution - 10 mg/ml - active: lamivudine 10 mg/ml excipient: banana flavour 010210 disodium edetate dihydrate p-hydroxybenzoic acid   propylene glycol purified water sodium citrate dihydrate sorbitol sucrose

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lamivudine, quantity: 300 mg - tablet, film coated - excipient ingredients: magnesium stearate; propylene glycol; microcrystalline cellulose; sodium starch glycollate type a; titanium dioxide; hypromellose - lamivudine tablets in combination with other antiretroviral agents is indicated for the treatment of hiv infected adults and children.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lamivudine, quantity: 150 mg - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate type a; propylene glycol; microcrystalline cellulose; titanium dioxide; hypromellose - lamivudine tablets in combination with other antiretroviral agents is indicated for the treatment of hiv infected adults and children.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lamivudine, quantity: 300 mg; abacavir sulfate, quantity: 702.78 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; silicified microcrystalline cellulose; purified talc; crospovidone; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - abacavir/lamivudine viatris tablets are a combination of two nucleoside analogues (abacavir and lamivudine). abacavir/lamivudine viatris is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lamivudine, quantity: 300 mg; abacavir sulfate, quantity: 702.76 mg (equivalent: abacavir, qty 600 mg) - tablet, film coated - excipient ingredients: hypromellose; titanium dioxide; sunset yellow fcf aluminium lake; macrogol 8000; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose - abacavir and lamivudine combination tablets are a combination of two nucleoside analogues (abacavir and lamivudine). ,abacavir and lamivudine combination tablets are indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

Singapur - angličtina - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - lamivudine - solution - 10 mg/ml - lamivudine 10 mg/ml

Spojené státy - angličtina - NLM (National Library of Medicine)

lannett company, inc. - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - lamivudine 10 mg in 1 ml - lamivudine oral solution, usp is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (hiv-1) infection.  limitations of use:   -  the dosage of this product is for hiv-1 and not for hbv. lamivudine oral solution is contraindicated in patients with a previous hypersensitivity reaction to lamivudine. pregnancy exposure registry   there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lamivudine during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263.  risk summary   available data from the apr show no difference in the overall risk of birth defects for lamivudine compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital defects program (macdp) reference population (see data) . the apr uses the macdp as the u.s. reference population for birth defects in the gene

Spojené státy - angličtina - NLM (National Library of Medicine)

marlex pharmaceuticals inc - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - lamivudine 10 mg in 1 ml - lamivudine oral solution, usp is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection. limitation of use: the dosage of this product is for hiv-1 and not for hbv. lamivudine oral solution is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., anaphylaxis) to any of the components of the products. teratogenic effects pregnancy category c. there are no adequate and well-controlled studies of lamivudine in pregnant women. animal reproduction studies in rats and rabbits revealed no evidence of teratogenicity. increased early embryolethality occurred in rabbits at exposure levels similar to those in humans. lamivudine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. lamivudine pharmacokinetics were studied in pregnant women during 2 clinical studies conducted in south africa. the study assessed pharmacokinetics i